Dr. Jay Skyler is internationally recognized for his pioneering leadership in diabetes research, clinical innovation, and education. As Chief Academic Officer of the Diabetes Research Institute Foundation and Professor of Medicine at the University of Miami, Dr. Skyler has dedicated his career to advancing therapies that transform the lives of people with diabetes.

He has led landmark NIH-funded clinical trials including the Type 1 Diabetes Prevention Trial (DPT-1) and TrialNet, shaping the global understanding of type 1 diabetes pathogenesis and intervention. A past President of the American Diabetes Association and founding Editor-in-Chief of Diabetes Care, Dr. Skyler has authored more than 500 scientific publications and 21 books.

Through his decades of work at the Diabetes Research Institute, Dr. Skyler continues to drive innovation in prevention, immunotherapy, and precision medicine for diabetes care worldwide.

Dr. Skyler’s leadership has shaped decades of diabetes innovation—spanning immunomodulation, intensive insulin therapy, and major NIH-funded clinical trials, including the Type 1 Diabetes Prevention Trial (DPT-1) and TrialNet. He has authored over 500 scientific publications and 21 books, and served as Editor-in-Chief of Diabetes Care.

A former President of the American Diabetes Association and a long-standing advisor to leading biotech and pharmaceutical companies, Dr. Skyler continues to advance research translating scientific discovery into improved diabetes outcomes worldwide.